Initial anticonvulsant monotherapy in routine care of children and adolescents: Levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness

European Journal of Pediatrics

Volumn 173, Issue 1, 2014, Pages 87-92

  Bertsche, Astrid ^a   Neininger, Martina P ^b   Dahse, Anna J ^a,b   Syrbe, Steffen ^a   Bernhard, Matthias K ^a   Frontini, Roberto ^a   Kiess, Wieland ^a   Bertsche, Thilo ^b   Merkenschlager, Andreas ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Adverse drug events; Children; Levetiracetam; Oxcarbazepine; Treatment effectiveness; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; OXCARBAZEPINE; VALPROIC ACID;

ADD ON THERAPY; ADOLESCENT; ANTICONVULSANT THERAPY; ARTICLE; ATTENTION DISTURBANCE; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CHILD; CHILD CARE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FAMILY; FATIGUE; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MOOD DISORDER; PHYSICIAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; PIRACETAM; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84893698252     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-013-2125-1     Document Type: Article

References (23)

1. Avner M, Finkelstein Y, Hackam D, Koren G (2007) Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale. Paediatr Drugs 9:267-270
2. Forsgren L, Beghi E, Oun A, Sillanpää M (2005) The epidemiology of epilepsy in Europe - a systematic review. Eur J Neurol 12:245-253
3. Gerstner T, Buesing D, Longin E, Bendl C, Wenzel D, Scheid B, Goetze G, Macke A, Lippert G, Klostermann W, Mayer G, Augspach-Hofmann R, Fitzek S, Haensch CA, Reuland M, Koenig SA (2005) Valproic acid induced encephalopathy - 19 new cases in Germany from 1994 to 2003 - a side effect associated to VPA-therapy not only in young children. Seizure 15:443-448
4. Koenig SA, Buesing D, Longin E, Oehring R, Häussermann P, Kluger G, Lindmayer F, Hanusch R, Degen I, Kuhn H, Samii K, Jungck A, Brückner R, Seitz R, Boxtermann W, Weber Y, Knapp R, Richard HH, Weidner B, Kasper JM, Haensch CA, Fitzek S, Hartmann M, Borusiak P, Müller-Deile A, Degenhardt V, Korenke GC, Hoppen T, Specht U, Gerstner T (2006) Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 47:2027-2031
5. Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle CE (2008) High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis 19:375-382
6. Kuba R, Novotná I, Brázdil M, Kocvarová J, Tyrlíková I, Mastík J, Rektor I (2010) Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. Acta Neurol Scand 121:83-88
7. Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314-319
8. Li J, Xiao N, Chen S (2011) Efficacy and tolerability of levetiracetam in children with epilepsy. Brain Dev 33:145-151
9. McVearry KM, Gaillard WD, VanMeter J, Meador KJ (2009) A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav 16:609-616
10. Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 16:1597-1605
11. Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2011) Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 134:396-404
12. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2012) Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 78:1207-1214
13. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW, NEAD Study Group (2013) Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol 12:244-252
14. Mula M, Trimble MR, Sander JW (2004) Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 13:55-57
15. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW (2003) Psychiatric adverse events during levetiracetam therapy. Neurology 61:704-706
16. Nadebaum C, Anderson V, Vajda F, Reutens D, Barton S, Wood A (2011) The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc 17:133-142
17. Nicolai J, Aldenkamp AP, Huizenga JR, Teune LK, Brouwer OF (2007) Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy. J Clin Psychopharmacol 27:221-224
18. Pronicka E, Weglewska-Jurkiewicz A, Pronicki M, Sykut-Cegielska J, Kowalski P, Pajdowska M, Jankowska I, Kotulska K, Kalicinski P, Jakobkiewicz-Banecka J, Wegrzyn G (2011) Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene. Med Sci Monit 17:CR203-CR209
19. Raspall-Chaure M, Lainez E, Toledo M, Salas-Puig J, Macaya-Ruiz A, Roig-Quilis M (2012) Reversible encephalopathy caused by valproic acid in an adolescent with idiopathic generalised epilepsy. Rev Neurol 55:663-668
20. Rosenow F, Schade-Brittinger C, Burchardi N, Bauer S, Klein KM, Weber Y, Lerche H, Evers S, Kovac S, Hallmeyer-Elgner S, Winkler G, Springub J, Niedhammer M, Roth E, Eisensehr I, Berrouschot J, Arnold S, Schröder M, Beige A, Oertel WH, Strzelczyk A, Haag A, Reif PS, Hamer HM, LaLiMo Study Group (2012) The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy - an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry 83:1093-1098
21. Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA, Liverpool Manchester Neurodevelopment Group, UK Epilepsy and Pregnancy Register (2011) Child dev following in utero expo: levetiracetam vs sodium valproate Neurol. Neurology 76:383-389
22. Trinka E, Marson AG, Van Paesschen W, Kälviäinen R, Marovac J, Duncan B, Buyle S, Hallström Y, Hon P, Muscas GC, Newton M, Meencke HJ, Smith PE, Pohlmann-Eden B, for the KOMET Study Group (2012) KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry. doi: 10.1136/jnnp-2011-300376
23. Wood H (2012) Epilepsy: psychiatric adverse effects of levetiracetam linked to genetic variation in dopamine signaling. Nat Rev Neurol 8:532